CN1253472C - 聚乙二醇人生长激素缀合物及其制备方法及其药物用途 - Google Patents
聚乙二醇人生长激素缀合物及其制备方法及其药物用途 Download PDFInfo
- Publication number
- CN1253472C CN1253472C CN 02132612 CN02132612A CN1253472C CN 1253472 C CN1253472 C CN 1253472C CN 02132612 CN02132612 CN 02132612 CN 02132612 A CN02132612 A CN 02132612A CN 1253472 C CN1253472 C CN 1253472C
- Authority
- CN
- China
- Prior art keywords
- hgh
- peg
- growth hormone
- human growth
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 50
- 102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 31
- 108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 31
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 16
- 230000008878 coupling Effects 0.000 claims abstract description 11
- 238000010168 coupling process Methods 0.000 claims abstract description 11
- 238000005859 coupling reaction Methods 0.000 claims abstract description 11
- -1 polyethylene Polymers 0.000 claims abstract description 8
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- 239000001488 sodium phosphate Substances 0.000 claims description 14
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 14
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 230000006320 pegylation Effects 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000011146 sterile filtration Methods 0.000 claims description 5
- 206010056438 Growth hormone deficiency Diseases 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 16
- 238000001727 in vivo Methods 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 abstract description 4
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 25
- 239000000126 substance Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 12
- 206010062767 Hypophysitis Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 238000005932 reductive alkylation reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- LRADVKQALJANQG-UHFFFAOYSA-N 2-chlorophenol;sodium Chemical compound [Na].OC1=CC=CC=C1Cl LRADVKQALJANQG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000019628 coolness Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- LDBSWFLQANRPNO-UHFFFAOYSA-N CN(C)C.B.CNC Chemical compound CN(C)C.B.CNC LDBSWFLQANRPNO-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02132612 CN1253472C (zh) | 2002-07-15 | 2002-07-15 | 聚乙二醇人生长激素缀合物及其制备方法及其药物用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02132612 CN1253472C (zh) | 2002-07-15 | 2002-07-15 | 聚乙二醇人生长激素缀合物及其制备方法及其药物用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1468863A CN1468863A (zh) | 2004-01-21 |
CN1253472C true CN1253472C (zh) | 2006-04-26 |
Family
ID=34145248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02132612 Expired - Lifetime CN1253472C (zh) | 2002-07-15 | 2002-07-15 | 聚乙二醇人生长激素缀合物及其制备方法及其药物用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1253472C (zh) |
-
2002
- 2002-07-15 CN CN 02132612 patent/CN1253472C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1468863A (zh) | 2004-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1273187C (zh) | 稳定性提高的无锌或低锌胰岛素制剂 | |
CN105121459A (zh) | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 | |
CN109851674B (zh) | 一种用于治疗儿童矮小症的重组人血清白蛋白/生长激素融合蛋白的制备纯化方法 | |
CN1423699A (zh) | 用于制备非免疫原性聚合物性缀合物的无聚集体尿酸氧化酶 | |
CN107080835A (zh) | 长效生长激素及其生产方法 | |
CN101743252A (zh) | 蛋白酶稳定化的、peg化的胰岛素类似物 | |
CN105061601A (zh) | 使用免疫球蛋白片段的胰岛素缀合物 | |
CN1181760A (zh) | 亲脂性肽类激素衍生物 | |
CN102634492A (zh) | 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用 | |
TWI281864B (en) | N-terminally monopegylated human growth hormone conjugates and process for their preparation | |
CN102010473A (zh) | 重组胃泌酸调节素融合蛋白及其制备和应用 | |
KR20150139982A (ko) | 제약학적으로 용도되는 신규한 뉴트린 접합체 | |
CN101534847A (zh) | 修饰型促红细胞生成素 | |
CN101163716B (zh) | 白细胞介素-6聚乙二醇结合物及其制备方法和应用 | |
WO2009121210A1 (zh) | 双链聚乙二醇修饰的生长激素及其制备方法和应用 | |
CN1253472C (zh) | 聚乙二醇人生长激素缀合物及其制备方法及其药物用途 | |
KR20080041661A (ko) | 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬 | |
TWI720939B (zh) | 長效型多肽及其生產和給藥的方法 | |
CN103619358A (zh) | 药物制剂 | |
CN1169827C (zh) | 一种增强多肽在体内稳定性药物的生产方法及其应用 | |
CN1651463A (zh) | 一种单甲氧基聚乙二醇-胰岛素复合物及其制备方法 | |
CN111484551B (zh) | 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子 | |
CN1145808A (zh) | 用于成年人的人生长激素制剂 | |
US20060134736A1 (en) | Human growth hormone conjugated with biocompatible polymer | |
ES2226326T3 (es) | Hormona de crecimiento humana para estimular la hematopoyesis y la reconstitucion del sistema inmune despues del trasplante de celulas madre hematopoyeticas en seres humanos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. Assignor: Wang Simian Contract fulfillment period: 2008.3.6 to 2022.7.15 Contract record no.: 2009220000019 Denomination of invention: Polyglycol-human growth hormone conjugate and its prepn process and medicinal use Granted publication date: 20060426 License type: Exclusive license Record date: 20090615 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.3.6 TO 2022.7.15; CHANGE OF CONTRACT Name of requester: CHANGCHUN JINSAI MEDICINE CO.,LTD. Effective date: 20090615 |
|
ASS | Succession or assignment of patent right |
Owner name: CHANGCHUN GENESCI PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: WANG SIMIAN Effective date: 20120525 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120525 Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Changchun, Jilin, Changchun Patentee before: Wang Simian |
|
C56 | Change in the name or address of the patentee |
Owner name: JINSAI MEDICINE CO., LTD., CHANGCHUN Free format text: FORMER NAME: CHANGCHUN GENSCI PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. |
|
CB03 | Change of inventor or designer information |
Inventor after: Wang Simian Inventor after: Feng Xiao Inventor before: Wang Simian |
|
COR | Change of bibliographic data | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: CHANGCHUN GENESCIENCE PHARMACEUTICAL Co.,Ltd. Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: CHANGCHUN GENESCIENCE PHARMACEUTICALS Corp. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060426 |